Utz Brands to Webcast Presentation at the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference on June 10
HANOVER, Pa.--(BUSINESS WIRE)--Utz Brands, Inc. (NYSE: UTZ) ('Utz' or the 'Company'), a leading U.S. manufacturer of branded Salty Snacks and a small-cap value Staples equity, announced today that the Company plans to webcast their presentation at the virtual Oppenheimer 25th Annual Consumer Growth and E-Commerce on June 10, 2025, at 12:45 p.m. ET.
The live webcast will be made accessible at the 'Events & Presentations' section of Utz's investor relations website at https://investors.utzsnacks.com/. The replay will be archived online for 90 days.
About Utz Brands, Inc.
Utz Brands, Inc. (NYSE: UTZ) manufactures a diverse portfolio of savory snacks through popular brands, including Utz®, On The Border® Chips & Dips, Zapp's®, and Boulder Canyon®, among others.
After over a century with a strong family heritage, Utz continues to have a passion for exciting and delighting consumers with delicious snack foods made from top-quality ingredients. Utz's products are distributed nationally through grocery, mass merchandisers, club, convenience, drug, and other channels. Based in Hanover, Pennsylvania, Utz has multiple manufacturing facilities located across the U.S. to serve our growing customer base. For more information, please visit the Company's website or call 1‐800‐FOR‐SNAX.
Investors and others should note that Utz announces material financial information to its investors using its Investor Relations website, U.S. Securities and Exchange Commission (the 'Commission') filings, press releases, public conference calls, and webcasts. Utz uses these channels, as well as social media, to communicate with our stockholders and the public about the Company, the Company's products, and other Company information. It is possible that the information that Utz posts on social media could be deemed to be material information. Therefore, Utz encourages investors, the media, and others interested in the Company to review the information posted on the social media channels listed on Utz's Investor Relations website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
32 minutes ago
- Business Wire
Teledyne FLIR's Black Hornet 4 Nano-Drone Approved for Defense Innovation Unit's Blue UAS List
BOSTON--(BUSINESS WIRE)--Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that its Black Hornet® 4 Personal Reconnaissance System has successfully completed the required NDAA and cyber security verification process and been approved for the Blue UAS List with an Authority to Operate. "We're honored to see Black Hornet 4 added to the Blue UAS List, knowing more operators across our military and government will be able to benefit from this one-of-a-kind drone and its distinct capabilities,' said Dr. JihFen Lei, president of FLIR Defense. Share Led by the Defense Innovation Unit (DIU), Blue UAS vets and verifies commercial drone technology for the Department of Defense and U.S. government. The Blue UAS List gives users access to a wide range of drone systems that can meet their diverse needs. In February Teledyne FLIR announced that Black Hornet 4 was selected by DoD operators from among more than 35 uncrewed aerial system (UAS) products, all rigorously tested during DIU's ' Blue UAS Refresh' event. 'We are honored to see Black Hornet 4 added to the Blue UAS List, knowing that more operators across our military and federal government will be able to benefit from this one-of-a-kind drone and its distinct capabilities,' said Dr. JihFen Lei, president of Teledyne FLIR Defense. 'DIU is filling a critical national need in meeting mission requirements by executing a more expansive Blue UAS program, and we have valued our partnership with them throughout the verification process.' Black Hornet 4 represents the next generation of lightweight nano-drones, able to provide enhanced covert situational awareness to small fighting units. Its 12-megapixel daytime camera and high-resolution thermal imager deliver crisp video and still images to the operator. At just 70 grams Black Hornet 4 can fly for more than 30 minutes, over three kilometers, and function in 25-knot winds and rain. Flight performance is augmented by advanced obstacle avoidance capabilities and other features. In May, FLIR Defense opened a new 13,000 sq ft facility in Somerset, Kentucky that will function as a major support hub for servicing, testing, and training on Black Hornet systems used by U.S. armed forces. FLIR Defense has delivered more than 33,000 Black Hornet drones to military and security forces in over 45 countries. The U.S. Army began acquiring Black Hornet systems in 2018 for its Soldier Borne Sensor (SBS) program. Since then, it has placed orders under SBS and other contract vehicles totaling more than $300 million. The award-winning Black Hornet is designed and built by Teledyne FLIR Defense in Norway. About Teledyne FLIR Defense Teledyne FLIR Defense has been providing advanced, mission-critical technology and systems for more than 45 years. Our products are on the frontlines of the world's most pressing military, security and public safety challenges. As a global leader in thermal imaging, we design and build sophisticated surveillance sensors for air, land and maritime use. We develop the most rugged, trusted unmanned air and ground platforms, as well as intelligent sensing devices used to detect chemicals, biological agents, radiation and explosives. At Teledyne FLIR Defense we bring together this expertise to deliver solutions that enable critical decisions and keep our world safe – from any threat, anywhere. To learn more, visit us online or follow @flir and @flir_defense. About Teledyne Technologies Teledyne Technologies is a leading provider of sophisticated digital imaging products and software, instrumentation, aerospace and defense electronics, and engineered systems. Teledyne's operations are primarily located in the United States, the United Kingdom, Canada, and Western and Northern Europe. For more information, visit Teledyne's website at
Business Wire
32 minutes ago
- Business Wire
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. ( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call. Please connect to the call using the following link: The event and accompanying slides can also be accessed by visiting the investor relations section of the company's website at An archived webcast will be available on the company's website following the event. The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge. In addition to safety and tolerability, the study assessed morphologic and inflammatory endpoints along with gluten challenge (GC) induced symptoms. FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endpoint (change from baseline). The mean VCIEL change from baseline was -1.849 for placebo subjects compared to 0.079 for FB102 treated subjects (p=0.0099). The change in the density of CD3-positive T cells, or IELs, from baseline was an increase of 13.3 for placebo subjects compared to a decline of 1.5 for FB102 treated subjects (p=0.0035). Baseline IEL density was 25.6 for the placebo subjects and 23.5 for the FB102 treated subjects. The mean change in the Vh:Cd ratio from baseline was -0.173 (0.21) for placebo subjects compared to -0.046 (0.09), a 73% improvement for FB102 treated subjects compared to placebo. Gluten challenge induced GI symptoms (nausea, vomiting, diarrhea, abdominal pain and abdominal bloating) reported during the 16 day gluten challenge from patient diaries/AE collection demonstrated a 42% benefit for FB102 treated subject (4.0 events per subject) compared to placebo (6.9 events per subject). There were no dropouts in the study. Treatment emergent adverse events (TEAE) were primarily mild (grade 1) with no grade 3 or higher SAEs reported in the FB102 arm. 'We want to congratulate all of the investigators and researchers that supported this study. I also want to acknowledge the incredible dedication and hard work of the Forte team. Celiac disease is debilitating for many patients with even trace exposure to gluten. FB102 has taken a big step forward towards addressing this very large unmet need with the results from this study. The Phase 2 celiac disease study is initiating with a topline readout expected in 2026.' said Paul Wagner, Ph.D. CEO and Chairperson of Forte Biosciences. 'These results are also very encouraging given the biology of the additional FB102 indications including vitiligo, alopecia areata and type 1 diabetes. We also look forward to reading out the topline results of the FB102 vitiligo study in the first half of 2026.' About Forte Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. Forward-Looking Statements Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential' or 'continue' or the negatives of these terms or other similar expressions. These statements are based on the Forte's current beliefs and expectations. Forward-looking statements include statements regarding Forte's beliefs, goals, intentions and expectations regarding its product candidate, FB102 and the therapeutic and commercial market potential of FB102, the expected timeline for the Phase 2 celiac study and related readout, and the expected timing of topline results for the FB102 vitiligo study. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: risks related to Forte's ability to obtain sufficient additional capital to continue to advance Forte's product candidate, FB102; uncertainties associated with the clinical development and regulatory approval of Forte's product candidate, FB102, including potential delays in the commencement, enrollment and completion of clinical trials; the risk that results from preclinical and the Phase 1b trials may not be predictive of future results from clinical trials; risks associated with the failure to realize any value from FB102 in light of inherent risks, expense and difficulties involved in successfully bringing product candidates to market; and additional risks, uncertainties, and other information affecting Forte's business and operating results is contained in Forte's Quarterly Report on Forms 10-Q filed on May 15, 2025, and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Source: Forte Biosciences, Inc.
Business Wire
40 minutes ago
- Business Wire
IonQ to Participate in Quantum Korea 2025 and Support Quantum Hackathon for Emerging Talent
COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced its participation in Quantum Korea 2025, taking place June 24–26 at the aT Center in Seoul. As part of its ongoing commitment to quantum education and ecosystem development, IonQ will also collaborate with Sungkyunkwan University to support a quantum hackathon aimed at fostering the next generation of quantum talent in South Korea. IonQ Chief Marketing Officer Margaret Arakawa and Chief Revenue Officer Rima Alameddine are scheduled to present the company's updated technology and business roadmap following the recent acquisitions of Oxford Ionics and Lightsynq, and a majority stake in ID Quantique (IDQ). The exhibit floor presentation entitled 'Exploring Quantum' is scheduled for Thursday, June 26, 2025 at 2:15 pm local time. IonQ will also demonstrate the IDQ Solteris Network Appliance, part of IDQ's Quantum Safe Ecosystem, designed to upgrade network infrastructure with quantum-safe encryption. This year marks IonQ's third consecutive sponsorship of Quantum Korea, a leading conference organized by South Korea's Ministry of Science and ICT that explores global trends in quantum innovations. IonQ executives will participate in key sessions, presenting updates on the company's technology roadmap and highlighting collaborations with South Korean partners. 'Global partnerships have been fundamental to IonQ's growth, and our collaborations in South Korea are among the most impactful,' said Niccolo de Masi, CEO of IonQ. 'We're proud to contribute to the vibrant quantum ecosystem in South Korea and to support initiatives that cultivate the next generation of quantum innovators.' IonQ's sponsorship of Quantum Korea continues its ongoing support of South Korea's quantum initiatives. The company has contributed to Korea's National Quantum Strategy and supported multiple quantum hackathons and academic initiatives. Most recently, IonQ signed agreements with Seoul National University and Sungkyunkwan University to support quantum research and workforce development. IonQ also signed a memorandum of understanding (MoU) with Busan Metropolitan City, Intellian, and the Korea Institute of Science and Technology Information (KISTI), with the intent to integrate IonQ's quantum technology into South Korea's high-performance computing infrastructure and support talent development initiatives. IonQ also announced plans to enter into a global quantum strategic partnership with SK Telecom, South Korea's largest wireless telecommunications operator. Conference attendees can meet IonQ representatives at Booth #B-07 where they can learn more about the company's roadmap, and its latest quantum networking innovations. About IonQ IonQ, Inc. is a leading commercial quantum computing and networking company, delivering high-performance systems aimed at solving the world's largest and most complex commercial and research use cases. IonQ's current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems and represent the forefront of the company's technological roadmap as it advances toward its goal of building quantum computers with 2 million physical qubits by 2030. The company's innovative technology and rapid growth were recognized in Newsweek's 2025 Excellence Index 1000, Forbes' 2025 Most Successful Mid-Cap Companies list, and Built In's 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words 'advances,' 'aimed,' 'available,' 'commitment,' 'contribute,' 'cutting-edge,' 'delivering,' 'forefront,' 'goal,' 'growth,' 'intent,' 'latest,' 'leading' 'ongoing,' 'plans,' 'solving,' 'strategic,' 'support,' 'will,' and other similar expressions are intended to identify forward-looking statements. These statements include those related to the IonQ's quantum computing capabilities and plans; IonQ's technology driving commercial quantum advantage or delivering scalable, fault-tolerant quantum computing in the future; the necessity, effectiveness, and future impacts of IonQ's offerings available today; and the scalability, fidelity, efficiency, accessibility, effectiveness, importance, reliability, performance, speed, impact, practicality, feasibility, and commercial-readiness of IonQ's offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ's ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ's ability to deliver, and customers' ability to generate, value from IonQ's offerings; IonQ's ability to sell effectively to government entities and large enterprises; IonQ's ability to implement its business plans, forecasts, roadmaps and other expectations, to identify and realize partnerships and opportunities, and to engage new and existing customers; IonQ's ability to effectively enter new markets; IonQ's ability to deliver services and products within currently anticipated timelines; IonQ's inability to effectively integrate its acquisitions of Qubitekk, Inc. and Lightsynq Technologies, Inc. assets and its acquisition of a majority interest in ID Quantique, SA; IonQ's customers deciding or declining to extend contracts into new phases; changes in government spending or policy that may affect IonQ's customers; and risks associated with government sales, including availability of funding and provisions that may allow the government to unilaterally terminate or modify contracts for convenience. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company's filings, including but not limited to those described in the 'Risk Factors' section of IonQ's filings with the U.S. Securities and Exchange Commission, including but not limited to the Company's most recent Annual Report on Form 10-K and reports on Form 10-Q. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.
